Christopher Ma1, Rocio Sedano2, Ahmed Almradi2, Niels Vande Casteele3, Claire E Parker4, Leonardo Guizzetti4, David F Schaeffer5, Robert H Riddell6, Reetesh K Pai7, Robert Battat8, Bruce E Sands9, Christophe Rosty10, Marla C Dubinsky11, Florian Rieder12, Noam Harpaz13, Maria T Abreu14, Robert V Bryant15, Gregory Y Lauwers16, Richard Kirsch6, Mark A Valasek17, Eileen Crowley18, William J Sandborn3, Brian G Feagan19, Rish K Pai20, Vipul Jairath19. 1. Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alimentiv Inc (formerly Robarts Clinical Trials, Inc), London, Ontario, Canada. Electronic address: christopher.ma@ucalgary.ca. 2. Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada. 3. Alimentiv Inc (formerly Robarts Clinical Trials, Inc), London, Ontario, Canada; Division of Gastroenterology, University of California San Diego, La Jolla, California. 4. Alimentiv Inc (formerly Robarts Clinical Trials, Inc), London, Ontario, Canada. 5. Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada. 6. Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, University of Toronto, Toronto, Ontario, Canada. 7. Division of Anatomic Pathology, Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania. 8. Jill Roberts Center for IBD, Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, New York. 9. Department of Medicine, The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York. 10. Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia; Envoi Pathology, Brisbane, Queensland, Australia. 11. Department of Pediatrics, Division of Pediatric Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York. 12. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio. 13. Department of Medicine, The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai Hospital, New York, New York; Department of Pathology, Molecular and Cell-Based Medicine and Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York. 14. Crohn's and Colitis Center, Division of Gastroenterology, Department of Medicine, University of Miami Leonard Miller School of Medicine, Miami, Florida. 15. Inflammatory Bowel Disease Service, Department of Gastroenterology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia; Faculty of Health Sciences, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia. 16. D.H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida. 17. Department of Pathology, University of California San Diego, La Jolla, California. 18. Division of Pediatric Gastroenterology, Western University, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada. 19. Alimentiv Inc (formerly Robarts Clinical Trials, Inc), London, Ontario, Canada; Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. 20. Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona.
Abstract
BACKGROUND & AIMS: Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. Our aim was to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for histologic response and remission after treatment. METHODS: An international, interdisciplinary expert panel of 19 gastroenterologists and gastrointestinal pathologists was assembled. A modified RAND/University of California, Los Angeles appropriateness methodology was used to address relevant issues. A total of 138 statements were derived from a systematic review of the literature and expert opinion. Each statement was anonymously rated as appropriate, uncertain, or inappropriate using a 9-point scale. Survey results were reviewed and discussed before a second round of voting. RESULTS: Histologic measurements collected using a uniform biopsy strategy are important for assessing disease activity and determining therapeutic efficacy in UC clinical trials. Multiple biopsy strategies were deemed acceptable, including segmental biopsies collected according to the endoscopic appearance. Biopsies should be scored for architectural change, lamina propria chronic inflammation, basal plasmacytosis, lamina propria and epithelial neutrophils, epithelial damage, and erosions/ulcerations. The Geboes score, Robarts Histopathology Index, and Nancy Index were considered appropriate for assessing histologic activity; use of the modified Riley score and Harpaz Index were uncertain. Histologic activity at baseline should be required for enrollment, recognizing this carries operational implications. Achievement of histologic improvement or remission was considered an appropriate and realistic therapeutic target. Current histologic indices require validation for pediatric populations. CONCLUSIONS: These recommendations provide a framework for standardized implementation of histopathology in UC trials. Additional work is required to address operational considerations and areas of uncertainty.
BACKGROUND & AIMS: Histopathology is an emerging treatment target in ulcerative colitis (UC) clinical trials. Our aim was to provide guidance on standardizing biopsy collection protocols, identifying optimal evaluative indices, and defining thresholds for histologic response and remission after treatment. METHODS: An international, interdisciplinary expert panel of 19 gastroenterologists and gastrointestinal pathologists was assembled. A modified RAND/University of California, Los Angeles appropriateness methodology was used to address relevant issues. A total of 138 statements were derived from a systematic review of the literature and expert opinion. Each statement was anonymously rated as appropriate, uncertain, or inappropriate using a 9-point scale. Survey results were reviewed and discussed before a second round of voting. RESULTS: Histologic measurements collected using a uniform biopsy strategy are important for assessing disease activity and determining therapeutic efficacy in UC clinical trials. Multiple biopsy strategies were deemed acceptable, including segmental biopsies collected according to the endoscopic appearance. Biopsies should be scored for architectural change, lamina propria chronic inflammation, basal plasmacytosis, lamina propria and epithelial neutrophils, epithelial damage, and erosions/ulcerations. The Geboes score, Robarts Histopathology Index, and Nancy Index were considered appropriate for assessing histologic activity; use of the modified Riley score and Harpaz Index were uncertain. Histologic activity at baseline should be required for enrollment, recognizing this carries operational implications. Achievement of histologic improvement or remission was considered an appropriate and realistic therapeutic target. Current histologic indices require validation for pediatric populations. CONCLUSIONS: These recommendations provide a framework for standardized implementation of histopathology in UC trials. Additional work is required to address operational considerations and areas of uncertainty.
Authors: Sripathi R Kethu; Subhas Banerjee; David Desilets; David L Diehl; Francis A Farraye; Vivek Kaul; Richard S Kwon; Petar Mamula; Marcos C Pedrosa; Sarah A Rodriguez; Louis-Michel Wong Kee Song; William M Tierney Journal: Gastrointest Endosc Date: 2010-10 Impact factor: 9.427
Authors: Kelly C Cushing; William Tan; David H Alpers; Vikram Deshpande; Ashwin N Ananthakrishnan Journal: Aliment Pharmacol Ther Date: 2019-11-07 Impact factor: 8.171
Authors: Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn Journal: Aliment Pharmacol Ther Date: 2020-09-27 Impact factor: 8.171
Authors: Britt Christensen; Stephen B Hanauer; Jonathan Erlich; Olufemi Kassim; Peter R Gibson; Jerrold R Turner; John Hart; David T Rubin Journal: Clin Gastroenterol Hepatol Date: 2017-02-24 Impact factor: 11.382
Authors: Katherine Li; Colleen Marano; Hongyan Zhang; Feifei Yang; William J Sandborn; Bruce E Sands; Brian G Feagan; David T Rubin; Laurent Peyrin-Biroulet; Joshua R Friedman; Gert De Hertogh Journal: Gastroenterology Date: 2020-08-25 Impact factor: 22.682
Authors: L Peyrin-Biroulet; W Sandborn; B E Sands; W Reinisch; W Bemelman; R V Bryant; G D'Haens; I Dotan; M Dubinsky; B Feagan; G Fiorino; R Gearry; S Krishnareddy; P L Lakatos; E V Loftus; P Marteau; P Munkholm; T B Murdoch; I Ordás; R Panaccione; R H Riddell; J Ruel; D T Rubin; M Samaan; C A Siegel; M S Silverberg; J Stoker; S Schreiber; S Travis; G Van Assche; S Danese; J Panes; G Bouguen; S O'Donnell; B Pariente; S Winer; S Hanauer; J-F Colombel Journal: Am J Gastroenterol Date: 2015-08-25 Impact factor: 10.864
Authors: Nazneen R Irani; Lai Mun Wang; Gary S Collins; Satish Keshav; Simon P L Travis Journal: J Crohns Colitis Date: 2018-11-09 Impact factor: 9.071
Authors: Joao M Serigado; Jennifer Foulke-Abel; William C Hines; Joshua A Hanson; Julie In; Olga Kovbasnjuk Journal: Front Med (Lausanne) Date: 2022-04-20
Authors: Olga Maria Nardone; Alina Bazarova; Pradeep Bhandari; Rosanna Cannatelli; Marco Daperno; Jose Ferraz; Martin Goetz; Xianyong Gui; Bu Hayee; Gert De Hertogh; Mark Lazarev; Ji Li; Adolfo Parra-Blanco; Luca Pastorelli; Remo Panaccione; Vincenzo Occhipinti; Timo Rath; Samuel C L Smith; Uday N Shivaji; Gian Eugenio Tontini; Michael Vieth; Vincenzo Villanacci; Davide Zardo; Raf Bisschops; Ralf Kiesslich; Subrata Ghosh; Marietta Iacucci Journal: United European Gastroenterol J Date: 2022-02-23 Impact factor: 4.623
Authors: Christopher Ma; Rish K Pai; David F Schaeffer; Jonathan Krell; Leonardo Guizzetti; Stefanie C McFarlane; John K MacDonald; Won-Tak Choi; Roger M Feakins; Richard Kirsch; Gregory Y Lauwers; Reetesh K Pai; Christophe Rosty; Amitabh Srivastava; Joanna C Walsh; Brian G Feagan; Vipul Jairath Journal: J Immunother Cancer Date: 2022-03 Impact factor: 12.469